|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer.
|
7908608 |
1994 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background The prognostic value of TP53 commutation in epidermal growth factor receptor (EGFR) mutant lung cancer is controversial and we therefore conducted this systematic review and meta-analysis.
|
30798634 |
2019 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study suggests that p53 codon 72 polymorphisms play a role in the development of lung cancer and modifies the risk for smoking-related lung cancer in a Chinese population.
|
23054019 |
2013 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
|
10226602 |
1999 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that p53 mutations in exon 7 might be associated with increased radiation sensitivity in these human lung cancer cell lines, but our data should be interpreted with caution since several other explanations might exist regarding what determines the response towards radiation.
|
12820372 |
2003 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together our results reveal a mechanism that p53 may inhibit cell migration by disrupting actin dynamics via Rad activation and implicate a tumor suppressor role of Rad in lung cancer.
|
21221513 |
2011 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to explore characteristics of DNA damage and TP53 gene mutations in lung cancer from Hungary.
|
19643813 |
2009 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ecotopic expression of wild-type p53, but not mutant p53 (R175H) suppressed both endogenous and exogenous 14-3-3γ in colon and lung cancer cell lines.
|
25384678 |
2015 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Epidermal Growth Factor Receptor-mutated Lung Cancer as the Initial Manifestation of Germline TP53 Mutation Associated Cancer.
|
29854570 |
2018 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using the April 2000 update of the p53 mutation database of the International Agency for Research on Cancer together with the primary literature, we confirm that the frequency of p53 G-->T transversions in lung cancer of smokers is about three times higher than their frequency in lung cancer of nonsmokers and in most other smoke-unrelated cancers.
|
12379456 |
2002 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Aim of our study was to evaluate the relationship between the polymorphisms of TP53 pathway genes <i>TP53</i>, <i>MDM2</i>, <i>MDM4</i>, the polymorphisms of HPV-associated genes <i>MTHFR</i>, <i>CASP8</i>, <i>CCR5</i>, and HPV infection with survival of LC patients.SNPs were genotyped using PCR-RFLP. qRT-PCR was used to detect, identify, and quantify HPV.
|
29423041 |
2018 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, no information is available on the combined effects of p53 gene transfer, chemotherapy, and radiation therapy on lung cancer growth in vitro and in vivo.
|
11555607 |
2001 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer.
|
15067062 |
2004 |
|
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that a new lung-targeting nanoparticle is capable of delivering miRNA mimics and siRNAs to lung adenocarcinoma cells in vitro and to tumors in a genetically engineered mouse model of lung cancer based on activation of oncogenic Kirsten rat sarcoma viral oncogene homolog (Kras) and loss of p53 function.
|
25114235 |
2014 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, a novel gene CSMD3 was identified as the second most frequently mutated gene (next to TP53) in lung cancer.
|
22510280 |
2012 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The identification of gene mutations in lung cancer has led to the development of inhibitory therapies, including antisense oligonucleotides and direct injection of tumor-suppressor genes, such as wild-type p53.
|
10550839 |
1999 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicate that hypomethylation status within exons 5-8 of p53 from peripheral lymphocyte DNA may be a relevant predictor of lung cancer among male smokers.
|
11205492 |
2001 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate regression analysis showed a moderate but statistically significant risk of lung cancer overall and especially of squamous-cell carcinoma (OR, 1.65; CI, 1.10-2.47) for TP53 72Pro allele carriers.
|
17059853 |
2007 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite the fact that many of the genetic alterations, including loss of heterozygocity in the 3p chromosome locus and point mutations in the tumor-suppressor genes TP53 and retinoblastoma (RB1), occur in nearly all histopathologic types of lung cancer, the frequency and the "timing" of their occurrence seems to differ between small-cell lung cancer (SCLC) cells, that are characterized by neuroendocrine differentiation, and non-small-cell lung cancer (NSCLC) cells.
|
19914087 |
2010 |
|
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that telomerase activity was detectable in 80% of 100 lung tumours, but only 7.7% of 91 paired adjacent normal tissues. p53 protein was overexpressed in 63% of the tumours but only 2% of the normal tissues. p53 was overexpressed in 56 of the 80 (70%) tumour tissues with telomerase activity but only seven of the 20 (35%) without telomerase activity. p53 protein overexpression carried a 6.7-fold (95% confidence interval, 1.7-27.7) increased risk for positive telomerase activity after adjustment by age, sex, ethnicity, smoking status and family history of lung cancer.
|
10408853 |
1999 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The high formation of BPDE-N(2)-dG adducts in bronchial epithelial cells and investigations showing that the profile of mutations induced by BPDE in these cells is similar to that seen in the p53 gene isolated from human lung tumors implicates benzo[a]pyrene as important carcinogen in tobacco-induced lung cancer in human beings.
|
15072824 |
2004 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that p53 is able to respond to exposure of arsenic or Cr(VI), suggesting that BEAS-2B cells are an appropriate in vitro model to investigate arsenic or Cr(VI) induced lung cancer.
|
26091798 |
2015 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Germ-free or antibiotic-treated mice were significantly protected from lung cancer development induced by Kras mutation and p53 loss.
|
30712876 |
2019 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiple logistic regression was used to estimate odds ratios (ORs) and 95% CIs for the risk of p53 mutation associated with polymorphisms of hOGG1 and APE1 in lung cancer.
|
23038158 |
2012 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After adjusting gender and tumor type, the major contributors to p53 degradation in lung cancer patients were determined to be p53 codon72 polymorphism and HPV 16/18 E6 oncoprotein expression.
|
23522190 |
2013 |